SCHEMBL3784901

SCHEMBL3784901

CCOC(=O)c1nc2c(Cl)cccc2n2cccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.45
ELANE P08246 6/20 0.44
KDM4E B2RXH2 3/20 0.44
MAPT P10636 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
CYP1A2 P05177 2/20 0.43
MAPK1 P28482 2/20 0.43
GABRA1 P14867 1/20 0.42
GABRA5 P31644 1/20 0.42
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1310922 0.80 PTPN2 (0.53) SMN1; SMN2ELANEKDM4EALDH1A1HPGD
SCHEMBL3790221 0.77 CDC25B (0.44) SMN1; SMN2ELANEKDM4EMAPTNPSR1
SCHEMBL3784898 0.77 KDM4E (0.48) SMN1; SMN2KDM4ENPSR1ALDH1A1HPGD
SCHEMBL3790285 0.75 SMN1; SMN2 (0.46) SMN1; SMN2KDM4EMAPTNPSR1ALDH1A1
SCHEMBL16516735 0.75 KDM4E (0.54) SMN1; SMN2ELANEKDM4ENPSR1ALDH1A1
SCHEMBL2783523 0.74 NPBWR1 (0.48) SMN1; SMN2KDM4EMAPTNPSR1ALDH1A1
SCHEMBL21439743 0.74 SPR (0.53) SMN1; SMN2ELANEKDM4EALDH1A1CYP1A2
SCHEMBL24455539 0.73 CYP1A2 (0.42) SMN1; SMN2ELANEKDM4EMAPTNPSR1
SCHEMBL8568089 0.72 CA12 (0.48) SMN1; SMN2KDM4EMAPTNPSR1ALDH1A1
SCHEMBL2779501 0.72 MAP3K5 (0.46) SMN1; SMN2KDM4EMAPTNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS PIM2, PIM1, PIM3 SMN1; SMN2 4553/4885ELANE 4586/4885KDM4E 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.